Date: 2011-01-28
Type of information: R&D agreement
Compound: biomarker predicting response to PF-01367338, drug candidate for PARP inhibition
Company: MDxHealth (Belgium) Pfizer (USA - NY) Newcastle University (UK) Cancer Research Technology Limited (CRT) UK
Therapeutic area: Cancer - Oncology
Type agreement: R&D development
Action mechanism:
Disease: ovarian cancer breast cancer
Details: MDxHealth SA has signed an agreement with Newcastle University (UK), Cancer Research Technology Limited (CRT) and Pfizer Inc. to collaborate on the identification and development of a biomarker predicting response to Pfizer, CRT and Newcastle University’s drug candidate for PARP inhibition, PF-01367338. The partners believe identification of a successful predictive biomarker could potentially lead to the development of a companion diagnostic to guide treatment decisions in ovarian and breast cancers. PF-01367338 works by inhibiting PARP1 and PARP2b enzymes involved in cellular DNA damage repair (DDR). As part of the collaboration, MDxHealth will profile the methylation patterns of DDR genes to seek to identify those involved in predicting tumor development and response to PARP inhibition. MDxHealth’s aim is to ultimately set up a high throughput platform that is clinically validated to rapidly test for epigenetic defects in key DDR genes to support the design and implementation of clinical trials to enable development of optimized, targeted therapies.
Financial terms: Financial terms were not disclosed.
Latest news:
